TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatient men and women, between the ages of 18 to 75 years, fluent in both written and spoken English.~* Employed for 20 hours or more for a minimum of 1 month prior to baseline.~* Primary diagnosis of Major Depressive Disorder with symptoms for at least 30 days prior to baseline.~Exclusion Criteria:~* Treatment with desvenlafaxine succinate sustained release at any time in the past and/or venlafaxine (Effexor or Effexor XR) 1 year prior to baseline.~* Treatment-resistant defined as any of the following failed treatments in the past 3 years: 3 or more previous adequate trials of \>=2 classes of antidepressant medication, electroconvulsive therapy, or psychotherapy (2 adequate trials).~* Current (within 12 months prior to the screening visit) psychoactive substance abuse or dependence (including alcohol), manic episode, posttraumatic stress disorder, obsessive-compulsive disorder, or a lifetime diagnosis of bipolar or psychotic disorder.~* Clinically important abnormalities on physical examination, electrocardiogram (ECG), or laboratory evaluations.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study in Patients With Chronic Obstructive Pulmonary Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients aged ≥ 40 years, who have signed an Informed Consent form prior to initiation of any study-related procedure or once applicable written informed consent obtained by legal representative.~2. Outpatients with a diagnosis of COPD and including:~   1. Smoking history of at least 10 pack years defined as \[(number of cigarettes smoked per day) x (number of years of smoking) / 20\], both current and ex-smokers are eligible.~  2. Use of bronchodilators in the previous 2 months to visit 1.~  3. Post-bronchodilator FEV1 \< 60% of the predicted normal value.~  4. Post-bronchodilator FEV1/FVC \< 0.7.~  5. A ≥ 5% response to a reversibility test.~  6. A Baseline Dyspnoea Index (BDI) focal score less or equal than 10 (to be met also at visit 2).~3. History of no more than one COPD exacerbation in the previous 12 months (without considering the last 2 months) to visit 1.~4. A cooperative attitude and ability to be trained to the proper use of pMDI and DPI (Accuhaler®, circular moulded plastic inhaler) inhalers.~Main Exclusion Criteria:~1. Clinically relevant respiratory disorders.~2. Current diagnosis of asthma or respiratory disorders other than COPD.~3. Clinically significant laboratory and ECG abnormalities indicating a significant or unstable concomitant disease which may impact the feasibility of the results of the study according to investigator's judgement.~4. Patients with COPD exacerbation in the 2 months prior to screening and during the study period.~5. Patients requiring long term (at least 12 hours daily) oxygen therapy for chronic hypoxemia.~6. Patients treated with depot corticosteroids in the 2 months preceding the visit 1 and during the run-in period.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Foster® (Type: EXPERIMENTAL): Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP extrafine 400 µg plus FF 24 µg).
- Seretide® Accuhaler® (Type: ACTIVE_COMPARATOR): Seretide® Accuhaler® (fluticasone 500 μg plus salmeterol 50 μg/actuation), 1 inhalation b.i.d. (daily dose of fluticasone 1000 μg plus salmeterol 100 μg).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab (TCZ) Administered to Participants With Giant Cell Arteritis (GCA).

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of GCA as classified according to protocol-specified criteria;~* Participants entering Period 1 must be receiving treatment with TCZ 8 mg/kg IV Q4W.~Exclusion Criteria:~* Treatment with any other investigational agent besides TCZ within 12 weeks (or 5 half-lives of the investigational drug, whichever is longer) prior to screening;~* Evidence of serious uncontrolled disease;~* Known active current or history of recurrent bacterial, viral, fungal, mycobacterial, or other infections;~* Active TB requiring treatment within the previous 3 years.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TCZ IV Q4W (Type: EXPERIMENTAL): Participants will receive up to 6 doses of Dose 1 of TCZ IV Q4W followed by up to 6 doses of Dose 2 of TCZ IV Q4W.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Hemodynamic Responses to RLX030 Infusion in Subjects With Acute Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients hospitalized or requiring admission to hospital for management of acute heart failure within the previous 48 hours.~* Pulmonary wedge pressure above or equal to18 mmHg determined by right heart catheterization~Exclusion Criteria:~* Systolic blood pressure below 115 mmHg~* Significant valvular diseases or arrythmias~* Acute coronary syndrome in previous 45 days~* Treatment with mechanical support (intra-aortic balloon pump, endotracheal intubation, mechanical ventilation, or any ventricular assist device)~* Impaired renal or hepatic function~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 87 Years
- Healthy Volunteers: f

Study Arms:
- RLX030 (Type: EXPERIMENTAL): RLX030 as intravenous infusion for 20 hours
- Placebo (Type: PLACEBO_COMPARATOR): Matching placebo as intravenous infusion for 20 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dexamethasone Intravitreal Implant in Retinal Vein Occlusion

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria were: age older than 18 years; CME secondary to retinal vein occlusion, disease duration inferior to 12 weeks; best-corrected visual acuity (BCVA) between 20/200 and 20/25 (Snellen equivalent) in the study eye at baseline examination, central retinal thickness (CRT) superior to 300 mm, as measured by optical coherence tomography at baseline examination.~The exclusion criteria were any ocular surgery in the study eye in the past 6 months; diabetes mellitus with signs of diabetic retinopathy; previous laser photocoagulation; previous intravitreal injection of corticosteroids or anti-vascular endothelial growth factor; a history of ocular inflammation; marked retinal ischemia or retinal hemorrhages (in particular in macular region involving the fovea); any other ocular condition such as anterior ischemic neuropathy, amblyopia or significant media opacities; significant alteration on epiretinal surface such as epiretinal membrane or vitreomacular traction; uncontrolled or advanced glaucoma; any uncontrolled systemic disease.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Macular Edema Patients (Type: None): Patients affected by cystoid macular edema (CME) due to retinal vein occlusion of recent onset (less than three months) will be enrolled.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Efficacy and Safety of Topiramate as Add on Treatment in Epilepsy Patients With Primary Generalized Tonic-clonic Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Body weight \>25 kilograms (55 pounds)~* diagnosis of primary generalized epilepsy~* must have primary generalized tonic-clonic (PGTC) seizures treated with 1 or 2 antiepileptic drugs~* must have three primary generalized tonic-clonic (PGTC) seizures during baseline period, with at least 1 during each 28-day period of baseline~* females must not have had their first menstrual period or be postmenopausal, or are physically incapable of child bearing, or if of child bearing potential, sexually abstinent, or using adequate birth control measures, and have a negative pregnancy test before study entry.~Exclusion Criteria:~* Patients who do not have epilepsy, such as those with a treatable cause of seizure (for example active infection or cancer)~* patients with progressive disorders (for example, active infection, cancer or metabolic disturbance)~* patients diagnosed with Lennox-Gastaut syndrome~* history of seizures occurring in only cluster patterns (numerous seizures occurring over a short period of time \[\<30 minutes\])~* documented history (previous 3 months) of generalized tonic-clonic status epilepticus (status epilepticus is a prolonged seizure or seizures repeated frequently over 20 to 30 minutes so that recovery between episodes does not occur) while receiving appropriate antiepileptic medication

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: - CKD patients requiring dialysis (HD, HDF, HF) for at least 1 month before enrolment - An iPTH determination within 14 days before randomisation must be greater than or equal to 300 pg/mL (biPTH greater than or equal to 150 pg/mL) - A serum calcium determination (corrected for calcium) within 14 days before randomisation must be greater than or equal to 8.4 mg/dL \[2.1 mmol/L\] Exclusion Criteria: - Have an unstable medical condition, defined as having been hospitalised, other than for dialysis vascular access revision, within 30 days before day 1, or otherwise unstable in the judgment of the investigator - Are currently breast-feeding - Are performing peritoneal dialysis - Have had a parathyroidectomy in the 3 months before day 1 - Have a gastrointestinal disorder that may be associated with impaired absorption of orally administered medications or an inability to swallow tablets

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- During dialysis visit (Type: ACTIVE_COMPARATOR): Cinacalcet is given during the dialysis visit
- Post-dialysis meal (Type: ACTIVE_COMPARATOR): Cinacalcet is administered with a post-dialysis meal

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison Between 7 and 14 Day Primaquine Combined With Dihydroartemisinin-piperaquine or 3 Day Chloroquine Radical Cure of P. Vivax (BPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 6 months old~* Microscopic diagnosis of Plasmodium vivax malaria mono-infection~* Participant or parent/guardian is willing and able to give informed consent for participation in the study~* Able (in the Investigators opinion) and willing to comply with all study requirements.~Exclusion Criteria:~* Severe malaria~* History of allergy or adverse reaction to artesunate, piperaquine, chloroquine, or primaquine~* Blood transfusion in the past 3 months~* G6PD deficiency by rapid test~* Hematocrit ≤ 25%~* Pregnancy at the time of screening~* Breastfeeding an infant \< 6 months old~* Presence of any condition which in the judgement of the investigator would place the subject at undue risk or interfere with the results of the study

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DHA-P 7 days (Type: EXPERIMENTAL): Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days and Primaquine 1 mg/kg once daily for 7 days
- DHA-P 14 days (Type: EXPERIMENTAL): Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days Primaquine 0.5 mg/kg daily for 14 days
- Chloroquine 7 days (Type: ACTIVE_COMPARATOR): Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 1 mg/kg once daily for 7 days
- Chloroquine 14 days (Type: ACTIVE_COMPARATOR): Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 0.5 mg/kg daily for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: X-ray Dose Reduction in Electrophysiology

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with heart rhythm disturbances undergoing an interventional treatment for their heart rhythm disturbance~* Patients who are allowed, able, willing to and have provided informed consent~* Patients to be treated with ablation for atrial fibrillation (paroxysmal, persistent or permanent), atypical atrial flutter or patients to be treated with ablation for ischemic or non-ischemic ventricular tachycardia~* Patients who are treated in heart catheterization room 5 (HCK5) of the Catherina Hospital~Exclusion Criteria:~* Patients under 18 years of age.~* Patient who are pregnant or breast feeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Regular X-ray dose settings (Type: ACTIVE_COMPARATOR): For patients in this group x-ray images are acquired with regular dose settings of the x-ray system and regular image processing
- Reduced X-ray dose settings (Type: EXPERIMENTAL): For patients in this group x-ray images are acquired with reduced dose settings of the x-ray system and advanced image processing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Recipient of a first-time kidney transplant~* Between the ages of 18 and 70 years, inclusive~Exclusion Criteria:~* Recipient of any non-kidney transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Treatment Arm 1 will also receive standard of care medications
- 2 (Type: EXPERIMENTAL): Treatment Arm 2 will also receive standard of care medications
- 3 (Type: EXPERIMENTAL): Treatment Arm 3 will also receive standard of care medications

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Avastin in Combination With Chemotherapy for RAS Mutant Unresectable Colorectal Liver-limited Metastases

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 and ≤ 75 years;~2. Primary tumour was histologically confirmed colorectal adenocarcinoma;~3. Together with clinical or radiological evidence of first occurrence of non-resectable liver-only metastases~4. With evidence of tumor RAS gene mutant status;~5. With at least one measurable tumor.~6. Performance status (ECOG) 0\~1~7. A life expectancy of ≥ 3 months~8. Adequate hematological function: Neutrophils≥1.5 x109/l and platelet count≥100 x109/l; Hb ≥9g/dl (within 1 week prior to randomization)~9. Adequate hepatic and renal function: Serum bilirubin≤1.5 x upper limit of normal (ULN), alkaline phosphatase ≤5x ULN, and serum transaminase (either AST or ALT) ≤ 5 x ULN(within 1 week prior to randomization);~10. Written informed consent for participation in the trial.~Exclusion Criteria:~1. Previous exposure to target therapy, chemotherapy, radiotherapy or intervention therapy for colorectal liver metastases.~2. Known or suspected extrahepatic metastases.~3. Patients with known hypersensitivity reactions to any of the components of the study treatments.~4. Having previously participated in a study which included a possibility of being allocated to avastin therapy (whether or not the patient actually received avastin)~5. Clinically relevant coronary artery disease or a history of a myocardial infarction within the last 12 months or left ventricular ejection fraction (LVEF) below the institutional range of normal~6. Acute or sub-acute intestinal occlusion~7. Pregnancy (absence confirmed by serum/urine β-HCG) or breast-feeding~8. Other previous malignancy within 5 years, with exception of a history of a previous basal cell carcinoma of the skin or pre-invasive carcinoma of the cervix~9. Known drug abuse/ alcohol abuse~10. Legal incapacity or limited legal capacity~11. Pre-existing peripheral neuropathy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ARM A (Type: EXPERIMENTAL): patients received avastin in combination with mFOLFOX6
- ARM B (Type: ACTIVE_COMPARATOR): Patients received mFOLFOX6 alone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Improving Outcomes for Individuals With Serious Mental Illness and Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Have Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder or major depression~2. Have DM based upon either previous diagnosis or laboratory values~3. Be ≥ 18 years of age~4. Be able to communicate in English~5. Be able to provide written, informed consent to participation.~Exclusion Criteria:~1. Actively suicidal/homicidal~2. Unable to be rated on study rating scales~3. Demented~4. Pregnant~5. Unable to provide informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Targeted Training in Illness Management (TTIM) (Type: EXPERIMENTAL): Participants in this arm will receive the TTIM intervention as well as receiving regular treatment for their DM and SMI from their normal medical and mental health care providers.
- Treatment As Usual (TAU) (Type: NO_INTERVENTION): Participants in this arm will continue to receive Treatment as Usual from their usual medical and mental health care providers. They will not receive any intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete